Preclinical characteristics of siRNA duplexes as targeted adjuvants in malignant growth

Background. Small or short double-stranded interfering RNAs (siRNAs, small interfering RNAs) 20–25 nucleotides long are known to be able to target block uncontrolled malignant proliferation. As target genes, apoptosis inhibitors are considered, including the cellular glycoprotein CD47 (cluster of differentiation 47), and genes of the replicative complex that regulate the cell cycle in the S phase. This determines the relevance of the study in tumor models of siRNAs aimed at these targets as adjuvants.

Aim. To evaluate the antiproliferative effects of novel siRNAs as adjuvants for immune-/chemotherapy in human colorectal and renal cancer models.

Materials and methods. SiRNA/antiCD47 and two-component siRNA antiMSM4/antiLIVIN were developed at the Research Centre for Medical Genetics and studied in lipid dispersion for intravenous (IV) administration. Preclinical models – subcutaneous xenographs of RTK-8 colon cancer and human kidney cancer Rpoch-1/CD47, Balb/c nude mice were obtained from the N.N. Blokhin National Medical Research Center of Oncology. In the adjuvant mode, siRNA/antiCD47 was studied in combination with activated human macrophages (AM), siRNA antiMSM4/antiLIVIN (1:1) – with cyclic-dependent cytostatic oxaliplatin (OXP). Administration regimens are justified earlier. Efficacy parameters and criteria (treatment/control (T/C) ≤42 %), tolerability of effects and statistical analysis at p <0.05 are standard for experimental cancer therapy. Laboratory manipulations are regulated by the current recommendations of the Ministry of Health of the Russia.

Results. The siRNA/anti-CD47 + AM regimen was practically ineffective at Rpoch-1/CD47, T/C = 45 % (p >0.05). The antiMCM4/antiLIVIN + 24 h siRNA regimen on an OXP-insensitive RTK-8 showed a significant adjuvant effect against cytostatic, T/C = 33–21 % versus T/C_min = 49 % (p ≤0.05). Both combinations were tolerable.

Conclusion. Preclinical study showed the controversy of the assumption about the possibility of adjuvant use of siRNA/antiCD47 with AM and the promise of antiMSM4/antiLIVIN siRNA on low-sensitivity to cycle-dependent OXR in human colon cancer with the possibility of cell cycle synchronization.

1. Setten R.L., Rossi J.J., Han S.P. The current state and future directions of RNAi-based therapeutics. Nature reviews. Drug Discovery 2019;18(6):421–46. DOI: 10.1038/s41573-019-0017-4

2. Hu B., Zhong L., Weng Y. et al. Therapeutic siRNA: state of the art. Sig Transduct Target Ther 2020;5(1):101. DOI: 10.1038/s41392-020-0207-x

3. Oh B.Y., Kim K.H., Chung S.S., Lee R.A. Silencing the livin gene enhances the cytotoxic effects of anticancer drugs on colon cancer cells. Ann Surg Treat Res 2016;91(6):273–7. DOI: 10.4174/astr.2016.91.6.273

4. Choi M.J., Kang S.J., Lee Y.K. et al. Novel lipid nanocomplex co-carrying Bcl2 siRNA and quantum dots for EGF receptor-targeted anti-cancer theranosis. Int J Mol Sci 2024;25(11):6246. DOI: 10.3390/ijms25116246

5. Li Y., Zou J., Zhang Q. et al. Systemic analysis of the DNA replication regulator MCM complex in ovarian cancer and its prognostic value. Front Oncol 2021;11(68):1261–8. DOI: 10.3389/fonc.2021.681261

6. Kim W., Ye Z., Simonenko V. et al. Codelivery of TGFβ and Cox2 siRNA inhibits HCC by promoting T-cell penetration into the tumor and improves response to Immune Checkpoint Inhibitors. NAR Cancer 2024;6(1):zcad059. DOI: 10.1093/narcan/zcad059

7. Lee J.W., Yoon H.Y., Ko Y.J. et al. Dual-action protein-siRNA conjugates for targeted disruption of CD47-signal regulatory protein α axis in cancer therapy. ACS nano 2024;18(33): 22298–315. DOI: 10.1021/acsnano.4c06471

8. Bartlett D.W., Davis M.E. Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res 2006;34(1):322–33. DOI: 10.1093/nar/gkj439

9. Luneva A.S., Puchkov P.A., Shmendel E.V. et al. Optimization of the technology for the preparation of cationic liposomes for the delivery of nucleic acids. Russ J Bioorg Chem 2018;44(6):724–31. DOI: 10.1134/S1068162019010084

10. Soriano P.A., Liu N., Castillo E. et al. Oxaliplatin but not irinotecan impairs posthepatectomy liver regeneration in a murine model. Int J Hepatol 2011;2011:490463. DOI: 10.4061/2011/490463

11. Treshalina H.M. Immunodeficient Balb/c nude mice and modeling of different tumor growth variants for preclinical studies. Rossijskij bioterapevticeskij zurnal = Russian Journal of Biotherapy 2017;16(3):6–12. (In Russ.). DOI: 10.17650/1726-9784-2017-16-3-6-13

12. Treshalina H.M. Collection of human tumor strains. Moscow: Practical Medicine, 2009. 171 p. (In Russ.).

13. Treshalina H.M., Zhukova O.S., Gerasimova G.K. et al. Guidelines for preclinical study of antitumor activity of drugs. In: Guidelines for preclinical studies of drugs. Moscow: Grif i K, 2012. Part 1. P. 642–657. (In Russ.).

14. Lewis B.M., Patial S., Saini Y. In vitro screening method for characterization of macrophage activation responses. Methods Protoc 2022;5(5):68. DOI: 10.3390/mps5050068

15. Karpukhin A.V., Alimov A.A., Maslov M.A., Kuzevanova A.Yu. Composition for inhibition of growth and stimulation of apoptosis of colorectal cancer cells. Patent RU 2 644 675 (13) C1. 2018. (In Russ.).